Chembond Material Technologies Limited passed all four resolutions with a requisite majority during its 51st Annual General Meeting held on July 17, 2026. The meeting, conducted via video conferencing, saw the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and the declaration of a final dividend on equity shares for the same period. Shareholders also re-appointed Jaywant K. Tawade as a director and approved remuneration for the Cost Auditor.

The remote e-voting facility, managed by National Securities Depository Limited (NSDL), was operational from July 14, 2026, to July 16, 2026. A total of 9,265,831 votes were polled, representing 68.8997% of the outstanding shares. Mr. Virendra Bhatt, Practicing Company Secretary, served as the Scrutinizer for the voting process and submitted the consolidated report.

The resolutions passed at the meeting covered both ordinary and special business items.

The voting results indicated strong support for the management's proposals. The resolution to adopt financial statements received 100% of the votes polled, while the dividend declaration also secured unanimous approval. The re-appointment of Jaywant K. Tawade passed with 99.9999% of the votes in favour, and the resolution to approve Cost Auditor remuneration was passed with 100% approval.

Chembond Material Technologies reported a 43.4% increase in consolidated net profit to ₹572.62 lakh for the quarter ended June 30, 2026, compared to ₹399.02 lakh in the corresponding period of the previous year. Revenue from operations rose 25.5% to ₹7,241.56 lakh from ₹5,767.50 lakh in the same quarter last year, driven by strong performance across its Specialty Chemicals and Animal Health segments. The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on July 17, 2026.

The Specialty Chemicals segment contributed ₹6,205.48 lakh to the net turnover, while the Animal Health segment added ₹1,036.08 lakh. Total expenses for the quarter stood at ₹7,035.12 lakh, up from ₹5,496.12 lakh in the year-ago period. Profit before tax for the quarter was ₹582.99 lakh, compared to ₹536.53 lakh in Q1FY26. The company’s basic earnings per share (EPS) improved to ₹4.26 from ₹2.97 in the previous year.

On a standalone basis, the company reported a net profit of ₹450.33 lakh for Q1FY27, up from ₹316.95 lakh in the corresponding quarter of the previous year. Revenue from operations increased to ₹6,296.89 lakh from ₹4,892.03 lakh. Profit before tax remained largely flat at ₹455.16 lakh compared to ₹457.28 lakh in the prior year. Standalone basic EPS for the quarter was recorded at ₹3.35.

The financial results were subjected to a limited review by the Statutory Auditors. The auditors noted that the comparative figures for the corresponding quarter ended June 30, 2025, were reviewed by the predecessor auditor. The group’s operations include the manufacture of Specialty Chemicals, Vitamins & Minerals, Probiotic and Prebiotic Enzymes, and Feed Additives.

Consolidated Financial Results (Q1FY27)

Standalone Financial Results (Q1FY27)